CCL27 is a C-C motif chemokine that functions as a chemotactic factor attracting skin-associated memory T-lymphocytes to cutaneous sites through binding to the CCR10 receptor 1. This chemokine plays a critical role in cutaneous immune homeostasis, with expression primarily localized to basal keratinocytes in healthy skin 1. The primary mechanism involves CCL27-CCR10 axis-mediated lymphocyte homing to the skin. In psoriasis, decreased CCL27 expression in basal keratinocytes potentially impairs this interaction, disrupting normal T-cell recruitment patterns 1. CCL27 expression can be used to distinguish inflammatory skin diseases; a two-gene classifier combining CCL27 and NOS2 reliably differentiates psoriasis from eczema in clinically unclear cases 2. Clinically, CCL27 serves as a diagnostic and prognostic biomarker in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), severe drug-induced diseases characterized by epidermal detachment 3 4. Elevated CCL27 levels have been identified as potential biomarkers for disease severity prediction in these life-threatening conditions 3 4. While CCL27 demonstrates promise in precision medicine approaches for inflammatory skin disease management, its clinical utility requires further validation alongside other emerging biomarkers.